Brian Cheek

Grow Everything podcast: In this episode, Damien Perriman, CCO of @eXoZymes and the commercial lead behind the NCTx spinout, breaks down why cell-free biomanufacturing changes the rules for scaling nature’s rare molecules. @Perriman states: “eXoZymes is building a disciplined model for bridging invention and market delivery. We remain focused on creating better ways to make important molecules, while vehicles like NCTx are designed to take those opportunities into the market with speed and purpose. When our process performs successfully in someone else’s hands at scale, it reinforces that cell-free biomanufacturing can be a practical commercial platform.” Full @messaginglab podcast episode available as both video and audio here: exozymes.com/blog/grow-ever… #exozymes #cellfree #biomanufacturing $EXOZ

From The @villagevoice: The Metabolic Engine - How Scientists Are Exploring a New Path Beyond GLP-1 Weight-Loss Drugs America’s weight-loss conversation has changed almost overnight. Prescription drugs once reserved for diabetes treatment are now household names, promising dramatic results on the scale. Many therapies currently available focus on reducing appetite or limiting calorie intake, which can certainly lead to weight loss. Yet those solutions often address the symptom rather than the deeper metabolic engine driving the condition. Interest is growing around strategies that target the body’s internal energy system itself. Instead of simply telling the body to eat less, researchers are investigating ways to improve how the body burns energy, processes fat, and maintains metabolic balance. That shift in thinking has opened the door to a small but intriguing molecule known as N-trans-Caffeoyltyramine, or NCT. Full story available here: na2.hubs.ly/H04N4_c0

CCO at @eXoZymes, Damien Perriman, interviewed at @Nasdaq around our NCT project: "We’ve shown that we can go from idea to 100× pilot scale in 12 months - and hit it right the first time. That kind of speed and predictability is exactly what this industry has been missing, and it’s what turns a single success into a repeatable value engine." #exozymes #exozyme #enzymes #enzyme #NCT #Nasdaq #ntranscaffeoyltyramine $EXOZ

It's time for another Heltzen's Video Highlight: 2025 in Review and Looking Ahead! In this video, I'm having conversations with our CSO, Tyler, and our CCO, Damien, about what happened last year and what we anticipate happening this year. Full video available here: na2.hubs.ly/H02S7b90